Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
dhvAgpamwJDNs54Y
